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Ovarian cancer is the most common
cause of death from gynecological cancer
in the western world, and despite
advances in treatment, the prognosis
remains poor for most women who devel-
op the disease. The reason for this is
mainly because in its early stages, it has
few, rather minor, symptoms and by the
time symptoms are persistent, the dis-
ease is often extensive, when treatment
failure is the rule.The overall five-year sur-
vival from ovarian carcinoma in the United
States in the years 1992–1997 was 52%,
but once disease was present outside of
the pelvis, the survival was only 29%
(h t t p : / /www.cance r. gov / cance r_
information). Newer drugs, such as pacli-
taxel (that prolong progres-
sion-free survival) have pro-
vided some hope for women
with late-stage disease
(McGuire et al., 1996), but
there have been no recent
research breakthroughs in
the basic understanding of
the disease. Part of the rea-
son for this may be that there
are no valid animal models of
this disease, and it is rarely
seen in domestic animals.
Guinea pigs and other
rodents do spontaneously
develop ovarian tumors, and
adding male and female sex
hormones to their feed can
induce ovarian tumors that
partly resemble human ovar-
ian carcinoma (Silva et al.,
1997). Nevertheless, these
rodent models are not suffi-
ciently faithful to the human disease to
have been particularly useful in under-
standing the prevention, natural history,
and treatment of ovarian carcinoma.
Given this preamble, the publication
of the paper by Orsulic et al. (2002) in the
inaugural issue of Cancer Cell is particu-
larly welcome. In brief, the authors used
their own technique to engineer mouse
ovarian cells to express the avian retrovi-
ral receptor, TVA. On removing the
ovaries from the mice, the team intro-
duced marker genes and oncogenes via
a retrovirus, RCAS (subgroup A).Tissue-
specific expression was enabled by
using β-actin and keratin promoters
(importantly, in the keratin 5-TVA cell
line, TVA receptor expression is limited
to the surface epithelium of the ovary).
The in vitro treated ovarian cells were
replaced in the mice at various sites.
Ovarian carcinomas resembling human
disease resulted (Figure 1), thus provid-
ing a flexible model for studying early
events, response to treatment, and pos-
sibly even ovarian cancer prevention.
What is particularly attractive about
the model is this flexibility. For example, in
this publication, the authors used c-myc,
K-ras, and Akt constructs singly, or in
combination, but as they point out, there
are many other genes, including the
members of the c-erbB family, that could
be applied in this system to generate
molecularly distinct models of ovarian
carcinoma. Indeed, it is in some ways a
bit surprising that the authors selected
K-ras, since the common codon 12
mutation is seen much more frequently
in human mucinous adenocarcinomas
and tumors of low malignant potential
than in the serous papillary tumors
(Caduff et al., 1999) that the tumors
occurring in the mice most closely resem-
ble. As one might expect from previous
studies, this model also differs from the
human situation in a number of interest-
ing ways. For example, in this model,
infection with all three of the above onco-
genes did not cause ovarian cancer at all
unless the mice were already null for
p53. Once p53−/− mice were crossed with
the TVA mice, then any two oncogenes
of the three used were sufficient to cause
ovarian carcinoma. This is quite unlike
the human situation, where heterozygos-
ity for germline TP53 mutations only very
rarely results in ovarian carcinoma
(Kleihues et al., 1997). The authors
address this by arguing that p53 alter-
ations are a necessary, but not initial,
event in ovarian carcinogenesis: in the
mouse model presented, such alterations
appear to be necessary and initial events.
It is not surprising that there
are some differences in the
molecular basis of experi-
mental ovarian carcinoma in
mice and the all-too-real
ovarian carcinoma in women.
It will be particularly interest-
ing to see whether the per-
missive effect of initial loss
of tumor suppressor gene
function is restricted to p53,
or whether other genes impli-
cated in ovarian carcinoma
susceptibility in humans,
such as PTEN and MSH2,
could also be important first
steps in ovarian carcino-
genesis. The authors refer
to some unpublished data
implicating INK4A/ARF, but
again, this is rather dissimilar
to the human situation,
where germline heterozy-
gous mutations in CDKN2A result in
increased susceptibility to cutaneous
malignant melanoma, pancreatic cancer,
and possibly breast and oral cancer, but
not to ovarian carcinoma. These obser-
vations raise the question of specificity:
Orsulic and her colleagues have elegant-
ly shown us that combined overexpres-
sion of selected oncogenes can cause
murine ovarian carcinoma that closely
resembles the human disease histo-
pathologically, but it remains to be seen
whether this effect is specific to the
choice of oncogenes. The fact that “any
two from three” will do, rather suggests
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Transgenic mouse model faithfully reproduces human ovarian carcinoma and offers new opportunities for understanding
the natural history of this frequently fatal disease.
Figure 1. Ovarian carcinomas induced in a mouse model (figure cour-
tesy of Orsulic et al., this issue).
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that the effects are not specific to these
three oncogenes, but further experiments
will be required to clarify the molecular
requirements for development of the dis-
ease in this system.
One of the important questions that
this paper has tried to answer is that of
the cell of origin of human ovarian carci-
noma. This may seem an unnecessary
question: as an ovarian carcinoma must-
n’t it, by definition, arise from an ovarian
epithelial cell? The immediate answer is
yes, but on further examination, it is not
quite so simple. Unlike almost all other
epithelial tumors, which occur common-
ly, ovarian carcinoma in situ is extremely
rare, and the benign-to-malignant trans-
formation of ovarian epithelium is sur-
prisingly infrequent. This curiosity along
with other observations regarding the
histopathology of the female genital
tract, has led some to question whether
in fact the carcinoma might arise from
proximal peritoneal epithelium rather
than the ovary itself (Dubeau, 1999).The
peritoneal epithelium is physically and
ontologically contiguous with the ovarian
surface epithelium, making the distinc-
tion reliant on physical contact of the lat-
ter with the ovarian stroma. Here, Orsulic
and colleagues argue persuasively for
an ovarian surface epithelial origin for
ovarian carcinoma, not only because
they used transplanted ovaries, but also
because the use of keratin- and β-actin-
specific promoters allowed the authors to
show unequivocally that the cancers
arose from the ovarian surface epitheli-
um. One could argue that some, but not
necessarily all, ovarian carcinomas have
been shown to arise from this surface,
but the ball is back in the court of the
naysayers.
The incidence of ovarian carcinoma
is disproportionately high relative to car-
cinomas of the peritoneum, and peri-
toneal carcinomas, when they do occur,
are found almost exclusively in women,
originate in the pelvic region, and are
often histologically indistinguishable
from ovarian carcinomas. Clearly there
must be something special about the
interactions between ovarian stroma and
peritoneal epithelium that promote the
neoplastic growth of the latter cell-type.
The greatest risk for both ovarian carci-
noma and this type of peritoneal cancer
is borne by women who carry germline
BRCA1 or BRCA2 mutations. In a recent
North American study of 208 Ashkenazi
Jewish women with ovarian carcinoma,
over 40% carried a BRCA1 or BRCA2
mutation (Moslehi et al., 2000).The ovar-
ian carcinomas that develop in BRCA1/2
mutation carriers closely resemble those
reported here in the murine model. In a
mouse model of human BRCA1-related
breast cancer developed by Deng and
colleagues who conditionally disrupted
Brca1 in mammary epithelial cells (Xu et
al., 1999), the incidence of breast tumors
was low unless the mice were crossed
into a p53+/− background. Within a year,
90% of the doubly mutant mice devel-
oped breast cancer that was accompa-
nied by loss of the wild-type p53 allele. It
will be interesting to see if alterations in
Brca1 or Brca2 will influence the pheno-
type reported by Orsulic et al.
The existence of a model may also
help with evaluating new treatments, as
the last really clear advance was the pro-
longation of survival provided by pacli-
taxel, mentioned previously. Ovarian car-
cinoma occurring in BRCA1/2 mutation
carriers appears to respond very well to
platinum-based therapies (Boyd et al.,
2000). A conditional knockout model of
Brca1-related ovarian cancer with the
ability to introduce specific oncogenic
alterations could be a very useful tool in
the further understanding of the basis of
the observed response.
The authors have described a flexi-
ble, if technically challenging, murine
model that offers new opportunities for
research into the causes and treatment
of human ovarian carcinoma. It will be
interesting to see how such models con-
tribute to the understanding of this dis-
ease when compared with easier and
more generally available techniques
such as expression microarray analysis
(Tonin et al., 2001).
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